Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology

Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results

Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018

Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia

Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases

Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson’s Disease

Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

Addex ADX71441 Pharmacological Profile Published in Neuropharmacology

Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer

Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia